Clinical trials
High Risk clinical trials
Below are recruiting high risk clinical trials, each written for real people, not researchers. We’re tracking 931 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06774417Recruiting
Digital strategies to help young people seek help for mental health
This trial tests a digital tool designed to help young people recognize early signs of mental health conditions and take steps toward getting help. It may be a good fit if you are between 12 and 29, live near certain research sites, and can complete a short screening questionnaire in English.
New York, New YorkAges 12–29 - NCT06774430Recruiting
Digital outreach for young people at risk of psychosis
This study tests a digital program designed to encourage young people to seek help for early signs of psychosis. It aims to see if online messages can increase connections to care.
New York, New YorkAges 12–29 - NCT06786234RecruitingPhase 2
STP938 for high-risk essential thrombocythemia
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
Poitiers, New AquitaineAges 18 years+ - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06802146RecruitingEarly Phase 1
Early treatment for high-risk CCUS
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
Boston, MassachusettsAges 18 years+ - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT06807606RecruitingPhase 2
Cord blood transplant after relapse from first transplant
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Houston, TexasAges Up to 60 years - NCT06810583RecruitingPhase 1
Dalbavancin to prevent infections in kids with leukemia
This trial tests if an antibiotic called dalbavancin can help prevent serious bacterial infections in children and young adults with high-risk leukemia whose immune systems are weakened by treatment.
Memphis, TennesseeAges Up to 25 years - NCT06810791RecruitingPhase 3
Comparing Chemotherapy Combos for High-Risk AML
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
Guangzhou, GuangdongAges 18 years+ - NCT06812598Recruiting
Extended letermovir to prevent CMV after stem cell transplant
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
Suzhou, JiangsuAges 18 years+ - NCT06816134RecruitingPhase 2
TmBU chemo before stem cell transplant for high-risk leukemia
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
Suzhou, JiangsuAges 15–65 - NCT06816121Recruiting
Blood test for early lung cancer in high-risk smokers
This study is evaluating a blood-based test that might detect lung cancer early, before symptoms appear. Researchers are looking for heavy smokers who have no signs of cancer, as well as those with suspicious lung nodules or confirmed lung cancer, to see if a simple blood draw could help identify cancer sooner.
Oklahoma City, OklahomaAges 30–80 - NCT06817239Recruiting
Low-dose esketamine for preventing confusion after surgery in older adults
This study tests whether a low dose of the medicine esketamine can help prevent confusion after surgery in older adults at higher risk. You may qualify if you are 65 or older, planning a major non-cardiac surgery, and have certain health conditions like high blood pressure or diabetes.
Fuzhou, FujianAges 65–90 - NCT06818682RecruitingPhase 2
Shortened hormone therapy with radiation for high-risk prostate cancer
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
Mumbai, MaharashtraAges 19–99 - NCT06819566RecruitingPhase 2
Preventing bleeding from enlarged veins in the esophagus
This study tests whether tying off high-risk veins in the esophagus before starting a common liver cancer treatment can prevent bleeding. It is for people with liver cancer that has spread but who have never had cancer treatment before.
Seoul, Song-paAges 19–80 - NCT06822010RecruitingPhase 2
Gemcitabine and Mitomycin for High-Risk Upper Tract Cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and mitomycin, given directly into the kidney or ureter through a thin tube. It is for people with a high-risk but non-invasive form of upper urinary tract cancer that has not spread into deeper tissues.
New Brunswick, New JerseyAges 18–99 - NCT06826859RecruitingPhase 1/Phase 2
Daily aspirin vs split dosing to prevent preeclampsia
This study compares taking a daily low-dose aspirin (a single pill) versus splitting the same dose into two smaller pills many hours apart to see which way better prevents preeclampsia in pregnant people who are at higher risk.
Philadelphia, PennsylvaniaAges 16–55 - NCT06830356Recruiting
PET-guided radiation for high-risk meningiomas
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
Aviano, PordenoneAges 16 years+ - NCT06835049RecruitingPhase 2
Heating therapy before surgery for high-risk soft tissue sarcoma
This trial tests a new approach for high-risk soft tissue sarcoma of the arm, leg, or trunk. Before surgery, you would receive chemotherapy combined with local hyperthermia (a treatment that gently heats the tumor area) to see if this can improve outcomes.
AarauAges 18 years+ - NCT06848582Recruiting
NK cell therapy for high-risk pediatric soft tissue sarcoma
This trial tests whether giving immune cells called NK cells from donated umbilical cord blood can help children and teens with high-risk or returning soft tissue sarcoma. The goal is to see if it is safe and effective when other treatments have been tried.
Guangzhou, GuangdongAges Up to 18 years - NCT06863545Recruiting
PCSK9 Inhibitors for High-Risk Coronary Plaques on CT
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
Hangzhou, ZhejiangAges 18 years+ - NCT06870435Recruiting
Screening for nasopharyngeal cancer with blood tests
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
Zhuhai, GuangdongAges 30–69 - NCT06872333RecruitingPhase 2
Stem cell transplant from a matched sibling for blood disorders
This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.
Minneapolis, MinnesotaAges Up to 55 years - NCT06880393RecruitingPhase 2
BCMA CAR-T for high-risk multiple myeloma
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
TianjinAges 18–75
Hear when a new High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk?
- Yes. Clin2 currently lists 931 recruiting high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.